Cardio Diagnostics Partners with Navierre to Expand Access to AI-Enabled Precision Cardiovascular Tests

Author:

Cardio Diagnostics Holdings, Inc. has announced a strategic partnership with Navierre, a digital health technology platform, to bring its AI-driven precision cardiovascular diagnostic tests to a wider audience. The collaboration aims to address the critical need for accessible and innovative clinical cardiovascular solutions, as heart disease remains the leading cause of death globally. Current solutions such as CT imaging are not highly scalable, especially in rural areas, due to the need for specialized infrastructure. In contrast, Cardio Diagnostics’ tests only require a blood sample and can be collected in various settings, including at-home or via mobile phlebotomy, enabling rapid scalability across the country.

By leveraging the growing telehealth market, Cardio Diagnostics and Navierre aim to revolutionize the patient cardiovascular care journey by enabling earlier detection, accessible specialty care, and personalized prevention. The AI-driven precision tests provided by Cardio Diagnostics utilize cutting-edge epigenetic and genetic science to offer personalized insights into a patient’s risk for coronary heart disease, providing actionable insights for proactive steps towards prevention and management.

Starting April 1, 2024, Cardio Diagnostics’ precision heart health tests will be available to thousands of patients and clinicians through Navierre’s platform. Clinicians can seamlessly order these tests for their patients, while consumers can easily register for a profile on the platform to request the clinical test after filling out a health questionnaire.

The partnership between Cardio Diagnostics and Navierre aims to make innovative diagnostic tools more accessible and convenient, ensuring that individuals can receive specialty cardiovascular care regardless of their location. This collaboration also underscores the commitment to health equity and access, particularly for underserved communities and those in remote areas. The goal is to create a future where no one is left behind in the fight against cardiovascular disease.

Cardio Diagnostics Holdings, Inc. operates in the healthcare industry, specifically focusing on cardiovascular diagnostic tests. The company aims to address the critical need for accessible and innovative clinical cardiovascular solutions, considering that heart disease remains the leading cause of death globally.

One of the main challenges in the industry is the scalability of current solutions such as CT imaging, especially in rural areas. These solutions require specialized infrastructure that may not be available in remote locations. In contrast, Cardio Diagnostics’ precision heart health tests only require a blood sample and can be collected in various settings, including at-home or through mobile phlebotomy. This enables rapid scalability and accessibility across the country.

Market forecasts for the cardiovascular diagnostic industry indicate significant growth due to the increasing prevalence of heart disease and the rising demand for early detection and personalized prevention. With the growing telehealth market, Cardio Diagnostics and its partner, Navierre, aim to revolutionize the patient cardiovascular care journey. The use of AI-driven precision tests that utilize cutting-edge epigenetic and genetic science can provide personalized insights into a patient’s risk for coronary heart disease.

By leveraging Navierre’s platform, Cardio Diagnostics will make its precision heart health tests available to thousands of patients and clinicians starting April 1, 2024. Healthcare providers can easily order these tests for their patients, while consumers can register for a profile on the platform and request the clinical test after filling out a health questionnaire. This streamlined process enhances accessibility and convenience for individuals seeking specialty cardiovascular care.

The strategic partnership between Cardio Diagnostics and Navierre emphasizes the importance of health equity and access. The collaboration aims to ensure that individuals, regardless of their location, can receive innovative diagnostic tools and specialty cardiovascular care. Underserved communities and those in remote areas will particularly benefit from this initiative.

Overall, the goal of this collaboration is to create a future where nobody is left behind in the fight against cardiovascular disease. By bringing AI-driven precision tests to a wider audience, Cardio Diagnostics and Navierre are driving advancements in the industry and striving to improve patient outcomes worldwide.

Related links:
1. Cardio Diagnostics Holdings, Inc.
2. Navierre